In This Article:
Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases
FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the official journal of the International Union of Immunological Societies.
In “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease,” Celularity scientists discuss how aging may influence the battle between the immune system and cancer, and the implications of senoablative Natural Killer, or NK, cells in disease progression. They emphasize that “preserving the function of NK cells during aging is essential for promoting healthy aging and longevity.” They conclude the publication by discussing the potential of adoptive NK cell therapy as a countermeasure to age-related decline in immunological function, a condition called immunosenescence.
Robert J. Hariri, M.D., Ph.D., a publication coauthor and Celularity Chairman and CEO, observed, “NK cell-based therapies demonstrate promise not only in treating cancer and viral infections but also a key role in rejuvenating the aging immune system, by eliminating senescent cells. This process, which we term “senoablation,” kills and clears senescent cells that exhibit a senescence-associated secretory phenotype (SASP), releasing toxic cytokines that promote inflammation and malignant transformation. Aside from the release of these toxic cytokines, senescent cells that remain in tissues block functional regeneration by healthy normal cells. We believe that eliminating these senescent cells could mitigate some of the negative effects of aging and offer clinical benefits in conditions such as age-related frailty and sarcopenia. Our clinical-stage, placental-derived allogeneic NK cell investigational candidate, CYNK-001, has been studied in over 70 subjects with acceptable safety and may represent a promising approach to addressing a range of conditions driven by cellular senescence.”
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com.